388 related articles for article (PubMed ID: 19342237)
1. Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer.
Schwartzberg LS; Cobb P; Senecal F; Henry D; Kulig K; Walker MS; Houts AC; Stepanski EJ
Breast; 2009 Apr; 18(2):78-83. PubMed ID: 19342237
[TBL] [Abstract][Full Text] [Related]
2. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
3. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
Buzdar A; Chlebowski R; Cuzick J; Duffy S; Forbes J; Jonat W; Ravdin P
Curr Med Res Opin; 2006 Aug; 22(8):1575-85. PubMed ID: 16870082
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant endocrine therapy for early breast cancer.
Andreetta C; Smith I
Cancer Lett; 2007 Jun; 251(1):17-27. PubMed ID: 17150303
[TBL] [Abstract][Full Text] [Related]
5. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
6. Anastrozole for breast cancer: recent advances and ongoing challenges.
Buzdar AU
Expert Rev Anticancer Ther; 2006 Jun; 6(6):839-48. PubMed ID: 16761927
[TBL] [Abstract][Full Text] [Related]
7. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Monnier AM
Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
[TBL] [Abstract][Full Text] [Related]
8. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
9. Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis.
van Herk-Sukel MP; van de Poll-Franse LV; Voogd AC; Nieuwenhuijzen GA; Coebergh JW; Herings RM
Breast Cancer Res Treat; 2010 Aug; 122(3):843-51. PubMed ID: 20058066
[TBL] [Abstract][Full Text] [Related]
10. Aromatase inhibitors in the management of early breast cancer.
Nabholtz JM
Eur J Surg Oncol; 2008 Nov; 34(11):1199-207. PubMed ID: 18359182
[TBL] [Abstract][Full Text] [Related]
11. A review of the BIG results: the Breast International Group 1-98 trial analyses.
Doughty JC
Breast; 2008 Jan; 17 Suppl 1():S9-S14. PubMed ID: 18279765
[TBL] [Abstract][Full Text] [Related]
12. Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.
Chlebowski RT
Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():25-34. PubMed ID: 19101792
[TBL] [Abstract][Full Text] [Related]
13. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy.
Cella D; Fallowfield LJ
Breast Cancer Res Treat; 2008 Jan; 107(2):167-80. PubMed ID: 17876703
[TBL] [Abstract][Full Text] [Related]
14. Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients -- a jungle?
Biganzoli L; Licitra S; Claudino W; Pestrin M; Leo AD
Eur J Cancer; 2007 Oct; 43(15):2270-8. PubMed ID: 17698345
[TBL] [Abstract][Full Text] [Related]
15. Safely promoting breast-conserving surgery and preventing early relapses with an aromatase inhibitor.
Markopoulos C
Surg Oncol; 2008 Aug; 17(2):113-28. PubMed ID: 18178077
[TBL] [Abstract][Full Text] [Related]
16. Optimising adjuvant endocrine treatment of breast cancer with aromatase inhibitors.
Fentiman IS
Int J Clin Pract; 2006 Jun; 60(6):689-93. PubMed ID: 16805754
[TBL] [Abstract][Full Text] [Related]
17. The evolution of adjuvant endocrine therapy: developments since St Gallen 2005.
Smith IE; Arnedos M
Breast; 2007 Dec; 16 Suppl 2():S4-9. PubMed ID: 17764939
[TBL] [Abstract][Full Text] [Related]
18. Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?
Tang SC
Cancer Invest; 2008 Jun; 26(5):481-90. PubMed ID: 18568770
[TBL] [Abstract][Full Text] [Related]
19. Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer.
Toi M; Yamashiro H; Tsuji W
Breast Cancer; 2009; 16(3):207-18. PubMed ID: 19259765
[TBL] [Abstract][Full Text] [Related]
20. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective.
Garreau JR; Delamelena T; Walts D; Karamlou K; Johnson N
Am J Surg; 2006 Oct; 192(4):496-8. PubMed ID: 16978958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
